Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapies

This page shows the latest cell and gene therapies news and features for those working in and with pharma, biotech and healthcare.

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Reflects growing investment in cell and gene therapies. Catalent has agreed a deal to buy Paragon Bioservices, a contract development and manufacturing organisation that specialises in complex biopharmaceuticals. ... The $1.2bn all-cash deal will give

Latest news

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    business model for cell and gene therapies is still being established. ... Vivet Therapeutics’ lead candidate is VTX-801, a gene therapy for Wilson disease, a devastating rare, chronic, and potentially life-threatening liver disorder.

  • NICE wants to stop saying ‘no’ – but needs pharma’s co-operation NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

    industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... This includes cell and gene therapies such as Novartis’ late-stage candidate Zolgensma, which the company has

  • NCI head Sharpless named as interim FDA chief NCI head Sharpless named as interim FDA chief

    therapies such as cell and gene therapies, whilst encouraging greater competition to products at the other end of their lifespan from generics and biosimilars. ... with efforts to revamp the clinical trial recruitment process and deploy ‘big data’ to

  • Oxford Biomedica taps Microsoft to progress gene therapy delivery tech Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

    These new technologies will help advance the next generation of cell and gene delivery approaches, the companies claim. ... Our goal is to enable faster, cheaper and more reliable manufacture of high quality next-generation cell and gene therapies to

  • Gene Genie Gene Genie

    This aims to find novel, more valid ways of valuing very expensive cell and gene therapies. ... That’s where the money lies, so that’s where evolution will lead the business models of cell and gene therapies.

More from news
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Minh Hong, head of commercial development for cell therapies at Swiss contract manufacturer Lonza, said: “There is so much variability between cell and gene therapies and each process at the moment, ... And even for allogeneic cell therapies and gene

  • Launch trends 2019 Launch trends 2019

    Companies also need to adapt to new commercialisation challenges for novel therapeutic modalities like gene and cell therapies. ... The transformational nature of some new therapies, eg cell and gene therapies, means the whole healthcare system delivery

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Gene and cell therapies, novel approaches to rare disease and drug replacements, like digital therapies, are about to crowd the market, creating gaps in education for physician and payer alike. ... an inflection point and quickly started a steep climb to

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Cell and gene therapies are not just revolutionising clinical outcomes, but also in how healthcare systems administer treatment to patients, and how those healthcare systems will pay for them. ... Cell and gene therapies undoubtedly do pose difficult

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and gene therapies for Novartis subsidiaries Systemix Inc.

  • Paul Blake joins Oxford BioMedica Paul Blake joins Oxford BioMedica

    He will head the clinical development of the company's pipeline of gene and cell therapies. ... therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from

  • Life at the end of the Brexit tunnel

    An Advanced Therapies Treatment Centre to develop cell and gene therapies. ... Expansion of the Cell and Gene Therapy Manufacturing Centre in Stevenage.

  • Introduction to the manufacturing of biologics

    However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or  ... polypeptides.  Examples of biologics  include blood or blood

  • The Clinical Trial Company

    The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market. ... TCTC are experts in advanced therapies, such as cell and gene therapies, as well as orphan drug and biologics.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics